Everself & Harvard Study Shows ESG Sustains Weight Loss After GLP-1s
Everself and Harvard research found ESG helped patients maintain significant weight loss after stopping GLP-1 medications.
Harvard Assistant Professor, Chair of American Society for Gastrointestinal Endoscopy's Advanced Endoscopy Committee, Everself Co-founder
This is one of the most common questions we hear from patients.
While GLP-1 medications have transformed obesity treatment, many individuals eventually discontinue therapy due to side effects, cost, insurance coverage, or personal preference. The challenge is what comes next.
Using real-world data from Everself and Harvard Medical School, a new study led by Everself co-founder and Harvard Medical School faculty member Dr. Pichamol Jirapinyo evaluated patients who discontinued GLP-1 therapy and pursued one of three strategies:
➡️ Endoscopic Sleeve Gastroplasty (ESG), a non-surgical weight loss procedure
➡️ Switching to another GLP-1 medication
➡️ Lifestyle modification alone
The results were notable:
• ESG was associated with ~18% total weight loss at 12 months
• Switching from one GLP-1 medication to another was associated with ~5% total weight loss
• Lifestyle modification alone resulted in minimal weight gain
The key takeaway: discontinuing a GLP-1 medication does not mean patients are out of options.
Obesity is a chronic disease, and long-term success often requires an individualized treatment plan and, in many cases, a sequential approach that combines or transitions between different therapies over time.
We’re excited to see this research highlighted by Medscape and grateful to the patients and collaborators who made this work possible.
Read the full article here:
